^
Association details:
| Biomarker: | BLK underexpression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Loss of BLK expression as a potential predictor of poor prognosis and immune checkpoint blockade response in NSCLC and contribute to tumor progression
Published date:
04/15/2023
Excerpt:
We found that the OS rate and DFS rate of low- expressing BLK was shorter than those of high-expressing BLK in LUAD (p=0.0043, p=0.015, Fig. 3A). The survival probability of high-expressing BLK was higher than low-expressing BLK in GSE3141 with primary lung tumors (p= 0.029, Fig. 3B)...the survival probability of high-expressing BLK was higher than that of low-expressing BLK in GSE8894 with NSCLC and GSE31210 with LUAD (Fig. 3F and 3G). Therefore, these results indicated that low expression of BLK was associated with poor prognosis....Our findings demonstrated that low expression of BLK may serve as biomarker for poor prognosis marker and response to ICB therapy in NSCLC.
DOI:
https://doi.org/10.1016/j.tranon.2023.101671
